読み込み中
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
前日終値
$3.89
+$0.01 · +0.26%
日中の時刻はETです。市場データは遅延する場合があります。
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
日中レンジ
現在 $3.89
52週レンジ
現在 $3.89
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
63
割安
センチメント
70
強気
リスク
51
やや高いリスク
モメンタム
73
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
日中レンジ
現在 $3.89
52週レンジ
現在 $3.89
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1214万 USD | 700万 USD | — | — | — |
| 売上原価 | 171.1万 USD | — | — | — | — |
| 粗利益 | 1042.9万 USD | 700万 USD | — | — | — |
| 研究開発 | 9430万 USD | 1.18億 USD | 1.03億 USD | 9288.9万 USD | 8677.8万 USD |
| 販売・一般管理 | 2240.6万 USD | 2871.9万 USD | 2888.4万 USD | 3065.1万 USD | 2695.7万 USD |
| 営業費用 | 1.15億 USD | 1.47億 USD | 1.32億 USD | 1.24億 USD | 1.14億 USD |
| 減価償却費と償却費 | 171.1万 USD | 177.2万 USD | 116.9万 USD | 132.4万 USD | 91.5万 USD |
| 営業利益 | −1.05億 USD | −1.4億 USD | −1.32億 USD | −1.24億 USD | −1.14億 USD |
| 純利益 | −9949.8万 USD | −1.27億 USD | −1.22億 USD | −1.15億 USD | −1.12億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.00
上昇余地（105.66%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI847.74万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM280.55万0.00%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF256.68万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO100.78万0.01%139.72億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO89.68万0.00%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC34.22万0.03%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM23万0.20%1.17億 USD0.73%$15.9402+0.25%
Vanguard Russell 2000 Growth ETFVTWG16.88万0.01%17億 USD0.06%$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
